ENIM Business Summary

Enimmune Corporation (6564.TWO) is a Taiwan-based biotechnology firm specializing in the research, development, and commercialization of vaccines and diagnostic reagents. The company generates revenue primarily through the sale of proprietary biological products, including the EnVAX-A71 vaccine for Enterovirus 71, the AdimFlu-S influenza vaccine, and various rapid diagnostic kits for infectious diseases such as COVID-19. Its business model is further supported by biotechnology services, drug testing, and international distribution agreements, notably in Southeast Asian markets. Within the competitive landscape, Enimmune operates alongside regional peers such as Medigen Vaccine Biologics, United BioPharma, and Sinovac Biotech, positioning itself as a specialized leader in the domestic production of pediatric and seasonal vaccines for the Asia-Pacific region. The leadership team is anchored by Chairman Chung-Cheng Liu, Ph.D., a Princeton-educated biochemist with a distinguished pedigree including research roles at Genentech and senior executive positions at the Industrial Technology Research Institute (ITRI). The day-to-day operations are led by President and CEO Vic Chang, who brings extensive financial and strategic planning experience from his previous tenure as CFO of Adimmune Corporation. Enimmune is a key subsidiary of Adimmune Corporation, Taiwan's largest vaccine manufacturer, and maintains a strong institutional investor base that includes notable entities such as Diamond Biofund and the Chung Ying Investment Development Company.